Impact of 80405 Study in Treatment Guidelines for CRC Patients
Alan P. Venook, MD, FASCO of Helen Diller Family Comprehensive Cancer Center discusses how the 80405 study in CRC patients impacted treatment guidelines at the 2017 Gastrointestinal Cancers Symposium ...
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Identifying Subgroups of HCC Patients That Are More Likely To Respond To Therapy
Alan P. Venook, MD, FASCO of Helen Diller Family Comprehensive Cancer Center talks of how he identifies subgroups of HCC patients that are more likely to respond to therapy at the 2017 Gastrointestina...
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
How are we integrating immunotherapy into existing treatment for gastric cancer patients
Alan P. Venook, MD, FASCO of Helen Diller Family Comprehensive Cancer Center discusses how healthcare professionals are integrating immunotherapy into existing treatment regimens for patients with gas...
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
How are we integrating immunotherapy into existing treatment for HCC patients
Alan P. Venook MD, FASCO of Helen Diller Family Comprehensive Cancer Center discusses integrating immunotherapy into existing treatment regimens for patients with HCC at the 2017 Gastrointestinal Canc...
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Integrating Immunotherapy Can Be a Challenge for CRC Patients
Alan P. Venook, M.D., FASCO of Helen Diller Family Comprehensive Cancer Center discusses how to integrate immunotherapy into existing treatment regimens for CRC patients at the 2017 Gastrointestinal C...
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Checkpoint Inhibitors are Active Agents in HCC
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses how checkpoint inhibitors will be used in unresectable HCC treatment at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Fran...
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Targeted Therapies for Patients with HCC
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses how targeted therapies seem to work better for patients with HCC at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisc...
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Regorafenib will be the Only Approved Agent in the Second Line
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses regorafenib in clinical practice at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA.
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2017: RESORCE Trial Results Define New Standard of Care
Thomas A. Abrams, MD of Dana Farber Cancer Institute gives an overview of the results of the RESORCE trial, that was presented at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco...
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Checkpoint Inhibitors for Advanced HCC Treatment
Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses new agents for the treatment of advanced HCC at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA.
Author: obr
Added: 01/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2017 Category: Cancer & Oncology Source Type: podcasts
Nivolumab Shows Significant Overall Survival Benefit in Metastatic Gastric Cancer
Ian Chau, MD, FRCP of Royal Marsden Hospital discusses how Nivolumab Shows Significant Overall Survival Benefit in Metastatic Gastric Cancer at ASCO GI 2017
Author: ASCOGI2017
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2017: Immunotherapy in Existing Treatment for GI Cancer Patients
Howard S. Hochster, MD of Yale Cancer Center discusses how healthcare professionals will be integrating immunotherapy into existing treatment regimens for GI cancer patients at the 2017 Gastrointestin...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Outcomes of Randomized Phase 2 Study in BRAF-Mutated CRC Patients
Howard S. Hochster, MD of Yale Cancer Center discusses the outcomes of the randomized phase 2 study in BRAF-mutated patients with colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (ASCO...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Genetic Profiling in Treatment Approach for Patients with CRC
Howard S. Hochster, MD of Yale Cancer Center discusses how genetic profiling has changed the treatment approach for patients with colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (ASCO...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Using Both TAS-102 and Regorafenib in Metastatic CRC Patients
Howard S. Hochster, MD of Yale Cancer Center discusses how to use both TAS-102 and Regorafenib in patients with metastatic colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
